Short Interest in IN8bio, Inc. (NASDAQ:INAB) Increases By 461.6%

Posted by Francis Steltz on Aug 28th, 2026

IN8bio, Inc. (NASDAQ:INAB – Get Free Report) saw a significant growth in short interest in the month of August. As of August 14th, there was short interest totaling 139,903 shares, a growth of 461.6% from the July 30th total of 24,913 shares. Approximately 1.7% of the company’s stock are short sold. Based on an average daily volume of 98,439 shares, the short-interest ratio is currently 1.4 days.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in INAB. HRT Financial LP purchased a new stake in shares of IN8bio during the 4th quarter worth about $34,000. Captrust Financial Advisors acquired a new stake in shares of IN8bio in the fourth quarter worth $43,000. Citadel Advisors LLC bought a new position in IN8bio during the third quarter valued at about $54,000. Texas Capital Bank Wealth Management Services Inc bought a new stake in IN8bio in the 4th quarter valued at $56,000. Finally, Two Sigma Investments LP acquired a new position in shares of IN8bio in the 3rd quarter worth approximately $107,000. Institutional investors and hedge funds own 92.05% of the company’s stock.

IN8bio Trading Up 0.9%

INAB stock traded up $0.01 on Friday, hitting $1.05. 4,390 shares of the company’s stock traded hands, compared to its average volume of 67,082. IN8bio has a 1-year low of $0.88 and a 1-year high of $2.73. The stock has a fifty day moving average of $1.23 and a 200-day moving average of $1.47. The stock has a market cap of $10.35 million, a price-to-earnings ratio of -0.65 and a beta of 0.24.

IN8bio (NASDAQ:INAB – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.09. On average, equities research analysts anticipate that IN8bio will post -1.25 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on INAB. Weiss Ratings restated a “sell (e+)” rating on shares of IN8bio in a report on Friday, July 17th. HC Wainwright reissued a “buy” rating on shares of IN8bio in a report on Thursday, June 4th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Read Our Latest Report on IN8bio

IN8bio Company Profile

(Get Free Report)

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.